[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MA38080A1 - Dérivés substitués de phtalazin-1(2h)-one comme inhibiteurs sélectifs de la poly(adp-ribose) polymérase-1 - Google Patents

Dérivés substitués de phtalazin-1(2h)-one comme inhibiteurs sélectifs de la poly(adp-ribose) polymérase-1

Info

Publication number
MA38080A1
MA38080A1 MA38080A MA38080A MA38080A1 MA 38080 A1 MA38080 A1 MA 38080A1 MA 38080 A MA38080 A MA 38080A MA 38080 A MA38080 A MA 38080A MA 38080 A1 MA38080 A1 MA 38080A1
Authority
MA
Morocco
Prior art keywords
pharmaceutically acceptable
adp
ribose
polymerase
poly
Prior art date
Application number
MA38080A
Other languages
English (en)
Inventor
Ranjit Desai
Brijesh Srivastava
Pankaj Patel
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54198806&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA38080(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Publication of MA38080A1 publication Critical patent/MA38080A1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30Phthalazines
    • C07D237/32Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La présente invention concerne des nouveaux composés de formule générale (i), leurs stéréoisomères, leurs régioisomères, leurs formes tautomères et des nouveaux intermédiaires impliqués dans leur synthèse, leurs sels pharmaceutiquement acceptables, leurs solvates pharmaceutiquement acceptables et des compositions pharmaceutiques les contenant. La présente invention concerne également un procédé de préparation des nouveaux composés de formule générale (i), de leurs stéréoisomères, de leurs régioisomères, de leurs formes tautomères, de leurs sels pharmaceutiquement acceptables, de leurs solvates pharmaceutiquement acceptables, de compositions pharmaceutiques les contenant et de nouveaux intermédiaires impliqués dans leur synthèse. Les composés de formule (i) sont utiles comme inhibiteurs de parp-1 pour le traitement, par exemple, du cancer.
MA38080A 2012-12-31 2013-12-23 Dérivés substitués de phtalazin-1(2h)-one comme inhibiteurs sélectifs de la poly(adp-ribose) polymérase-1 MA38080A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3742MU2012 2012-12-31
PCT/IN2013/000794 WO2014102817A1 (fr) 2012-12-31 2013-12-23 Dérivés substitués de phtalazin-1(2h)-one comme inhibiteurs sélectifs de la poly(adp-ribose) polymérase-1

Publications (1)

Publication Number Publication Date
MA38080A1 true MA38080A1 (fr) 2018-02-28

Family

ID=54198806

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38080A MA38080A1 (fr) 2012-12-31 2013-12-23 Dérivés substitués de phtalazin-1(2h)-one comme inhibiteurs sélectifs de la poly(adp-ribose) polymérase-1

Country Status (30)

Country Link
US (1) US9598418B2 (fr)
EP (1) EP2938598B1 (fr)
JP (1) JP5930452B2 (fr)
KR (1) KR101652654B1 (fr)
CN (1) CN104918917A (fr)
AP (1) AP2015008439A0 (fr)
AR (1) AR094299A1 (fr)
AU (1) AU2013368842B2 (fr)
BR (1) BR112015012425A2 (fr)
CA (1) CA2890309A1 (fr)
CL (1) CL2015001655A1 (fr)
CO (1) CO7400872A2 (fr)
DK (1) DK2938598T3 (fr)
EA (1) EA201591239A1 (fr)
ES (1) ES2614885T3 (fr)
GE (1) GEP201706691B (fr)
HK (1) HK1210466A1 (fr)
HR (1) HRP20170219T1 (fr)
HU (1) HUE030613T2 (fr)
IL (1) IL238714A0 (fr)
MA (1) MA38080A1 (fr)
MX (1) MX2015006780A (fr)
NZ (1) NZ708255A (fr)
PH (1) PH12015501199B1 (fr)
PL (1) PL2938598T3 (fr)
PT (1) PT2938598T (fr)
SG (1) SG11201503670YA (fr)
TW (1) TWI553005B (fr)
WO (1) WO2014102817A1 (fr)
ZA (1) ZA201503218B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
RS56776B1 (sr) 2013-11-26 2018-04-30 Hoffmann La Roche Derivati oktahidro-ciklobuta [1,2-c;3,4-c']dipirola kao inhibitori autotaksina
EA037928B1 (ru) 2014-03-26 2021-06-08 Ф. Хоффманн-Ля Рош Аг Бициклические соединения в качестве ингибиторов продукции аутотаксина (atx) и лизофосфатидиловой кислоты (lpa)
WO2016187620A2 (fr) 2015-05-21 2016-11-24 The Regents Of The University Of California Composés anti-cancereux
CA2992889A1 (fr) 2015-09-04 2017-03-09 F. Hoffmann-La Roche Ag Derives de phenoxymethyle
RU2018114289A (ru) 2015-09-24 2019-10-24 Ф. Хоффманн-Ля Рош Аг Бициклические соединения в качестве ингибиторов аутотаксина (atx)
BR112017026682A2 (pt) 2015-09-24 2018-08-14 Hoffmann La Roche novos compostos bicíclicos como inibidores de dupla ação de atx/ca
WO2017050792A1 (fr) * 2015-09-24 2017-03-30 F. Hoffmann-La Roche Ag Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
JP6877413B2 (ja) * 2015-09-24 2021-05-26 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 二重atx/ca阻害剤としての新規な二環式化合物
WO2017071636A1 (fr) * 2015-10-30 2017-05-04 四川科伦博泰生物医药股份有限公司 Dérivé de phthalazine cétone, son procédé de préparation et son utilisation
WO2017101796A1 (fr) * 2015-12-16 2017-06-22 四川科伦博泰生物医药股份有限公司 Dérivé de phtalazinone, et procédé de préparation et utilisation associés
WO2017223516A1 (fr) 2016-06-24 2017-12-28 The Regents Of The University Of California Dérivés de phtalazine utiles en tant qu'inhibiteurs de parp1, parp2 et/ou de tubuline dans le traitement du cancer
BR112019019017A2 (pt) 2017-03-16 2020-04-14 Hoffmann La Roche compostos heterocíclicos de utilidade como inibidores duplos de atx/ca
JP7090099B2 (ja) 2017-03-16 2022-06-23 エフ.ホフマン-ラ ロシュ アーゲー Atxインヒビターとしての新規二環式化合物
ES2747768T3 (es) 2017-03-20 2020-03-11 Forma Therapeutics Inc Composiciones de pirrolopirrol como activadores de quinasa de piruvato (PKR)
CN109251204A (zh) * 2017-07-13 2019-01-22 中国药科大学 含有酞嗪-1(2h)-酮结构的parp抑制剂、其制法及医药用途
CN108164468B (zh) * 2018-02-09 2021-02-02 上海卫岑医药科技有限公司 一种parp抑制剂、其药物组合物、制备方法及应用
CN113166060B (zh) 2018-09-19 2024-01-09 诺沃挪第克健康护理股份公司 用丙酮酸激酶激活化合物治疗镰状细胞病
CN113226356A (zh) 2018-09-19 2021-08-06 福马治疗股份有限公司 活化丙酮酸激酶r
EP4148046A4 (fr) * 2020-05-08 2024-07-24 Txinno Bioscience Inc Nouveau dérivé de phtalazine ayant une activité d'inhibition de l'ectonucléotide pyrophosphatase/phosphodiestérase, et son utilisation
WO2022192745A1 (fr) * 2021-03-11 2022-09-15 Mirati Therapeutics, Inc. Inhibiteurs de prmt5 coopératif à base de mta
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R
US20240317762A1 (en) * 2021-07-16 2024-09-26 Oregon Health & Science University Phthalazinone-based parp-1 inhibitors
CN118871432A (zh) * 2022-03-15 2024-10-29 百济神州有限公司 作为prmt5的mta协同抑制剂的4-(氨基甲基)-6-(1-甲基-1h-吡唑-4-基)异喹啉-1(2h)-酮衍生物
WO2024046420A1 (fr) * 2022-08-31 2024-03-07 江苏恒瑞医药股份有限公司 Composé bicyclique fusionné, son procédé de préparation et son utilisation en médecine

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6531464B1 (en) 1999-12-07 2003-03-11 Inotek Pharmaceutical Corporation Methods for the treatment of neurodegenerative disorders using substituted phenanthridinone derivatives
CN100400518C (zh) 2000-10-30 2008-07-09 库多斯药物有限公司 2,3-二氮杂萘酮衍生物
US7449464B2 (en) * 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
EA009469B1 (ru) 2003-03-12 2007-12-28 Кудос Фармасеутикалс Лимитед Производные фталазинона
WO2005066163A2 (fr) 2004-01-05 2005-07-21 Astrazeneca Ab Heterocycles substitues et leurs utilisations
MX2007002318A (es) 2004-08-26 2007-04-17 Kudos Pharm Ltd Derivados de ftalazinona substituidos con 4-heteroarilmetilo.
US20060079510A1 (en) 2004-09-30 2006-04-13 Kristoffer Hellstrand Use of PARP-1 inhibitors for protecting tumorcidal lymphocytes from apoptosis
MX2007012448A (es) 2005-04-06 2007-10-19 Astrazeneca Ab Heterociclos sustituidos y su uso como inhibidores de chk1, pdk1 y pak.
DE602006020335D1 (de) 2005-11-25 2011-04-07 Pharma Mar Sa Verwendung von parp-1-hemmern
GB0610680D0 (en) * 2006-05-31 2006-07-12 Istituto Di Ricerche D Biolog Therapeutic compounds
TWI404716B (zh) 2006-10-17 2013-08-11 Kudos Pharm Ltd 酞嗪酮(phthalazinone)衍生物
US8466150B2 (en) * 2006-12-28 2013-06-18 Abbott Laboratories Inhibitors of poly(ADP-ribose)polymerase
HUE027641T2 (en) 2006-12-28 2016-11-28 Abbvie Inc Poly (ADP-ribose) polymerase inhibitors
CA2687786A1 (fr) 2007-05-25 2008-12-04 Astrazenca Ab Combinaison d'inhibiteurs de chk et de parp dans le traitement du cancer
US20090023727A1 (en) * 2007-07-05 2009-01-22 Muhammad Hashim Javaid Phthalazinone derivatives
EP2220073B1 (fr) 2007-11-15 2014-09-03 MSD Italia S.r.l. Derivés de pyridazinone inhibiteurs de la parp
UY31603A1 (es) 2008-01-23 2009-08-31 Derivados de ftalazinona
MY160340A (en) 2008-10-07 2017-02-28 Astrazeneca Uk Ltd Pharmaceutical formulation 514
JP2013532683A (ja) 2010-07-27 2013-08-19 カディラ ヘルスケア リミティド ポリ(adpリボース)ポリメラーゼ−1阻害剤としての、置換4−(4−フルオロ−3−(ピペラジン−1−カルボニル)ベンジル)フタラジン−1(2h)−オン誘導体
CN102372706A (zh) * 2010-08-09 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
CN102372716A (zh) * 2010-08-09 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
CN102372698A (zh) * 2010-08-10 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
US8999985B2 (en) * 2010-12-02 2015-04-07 Shanghai De Novo Pharmatech Co Ltd. Substituted phthalazin-1(2H)-ones, preparation processes and medical uses thereof
CN102485721B (zh) 2010-12-03 2015-12-09 曹亚 取代的2,3-二氮杂萘酮化合物及其用途
CN103717609B (zh) 2011-05-31 2016-05-11 江苏康缘药业股份有限公司 聚(adp-核糖)聚合酶的三环抑制剂
JP5927071B2 (ja) 2011-07-13 2016-05-25 参天製薬株式会社 Parp阻害活性を有する新規化合物
US20130053365A1 (en) 2011-08-30 2013-02-28 Biomarin Pharmaceutical, Inc. Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp)
WO2013097226A1 (fr) 2011-12-31 2013-07-04 Beigene, Ltd. Pyridophthalazinones tétra ou pentacycliques fusionnés à utiliser en tant qu'inhibiteurs de parp
EA026611B1 (ru) 2012-02-09 2017-04-28 Мерк Патент Гмбх Производные тетрагидрохиназолинона в качестве ингибиторов tank и parp
CN103242273B (zh) 2012-02-09 2015-06-03 中国科学院上海药物研究所 2-芳基苯并呋喃-7-甲酰胺类化合物、其制备方法及用途

Also Published As

Publication number Publication date
DK2938598T3 (en) 2017-02-13
PH12015501199A1 (en) 2015-08-17
US20150291603A1 (en) 2015-10-15
AP2015008439A0 (en) 2015-05-31
IL238714A0 (en) 2015-07-01
SG11201503670YA (en) 2015-07-30
US9598418B2 (en) 2017-03-21
HUE030613T2 (en) 2017-05-29
PL2938598T3 (pl) 2017-05-31
EP2938598B1 (fr) 2016-12-21
AU2013368842B2 (en) 2015-11-12
JP2016504347A (ja) 2016-02-12
HK1210466A1 (en) 2016-04-22
CO7400872A2 (es) 2015-09-30
HRP20170219T1 (hr) 2017-04-07
MX2015006780A (es) 2015-08-06
CN104918917A (zh) 2015-09-16
PH12015501199B1 (en) 2015-08-17
AU2013368842A1 (en) 2015-05-21
CA2890309A1 (fr) 2014-07-03
KR101652654B1 (ko) 2016-08-30
EP2938598A1 (fr) 2015-11-04
TW201441219A (zh) 2014-11-01
ES2614885T3 (es) 2017-06-02
EA201591239A1 (ru) 2015-10-30
CL2015001655A1 (es) 2015-10-02
PT2938598T (pt) 2017-02-07
JP5930452B2 (ja) 2016-06-08
AR094299A1 (es) 2015-07-22
ZA201503218B (en) 2016-01-27
TWI553005B (zh) 2016-10-11
KR20150091137A (ko) 2015-08-07
BR112015012425A2 (pt) 2017-07-11
GEP201706691B (en) 2017-06-26
NZ708255A (en) 2016-08-26
WO2014102817A1 (fr) 2014-07-03

Similar Documents

Publication Publication Date Title
MA38080A1 (fr) Dérivés substitués de phtalazin-1(2h)-one comme inhibiteurs sélectifs de la poly(adp-ribose) polymérase-1
MA32135B1 (fr) Inhibiteurs de pim kinase et leurs procedes d'utilisation
TN2009000450A1 (fr) Derives de pyridine
MA38138A1 (fr) Dérivés inédits de quinolone
TN2014000033A1 (fr) Indazoles
MA41134B1 (fr) Composés substitués de 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione pour le traitement et la prophylaxie des infections virales
MY155653A (en) Triazine compounds as p13 kinase and mtor inhibitors
MA31574B1 (fr) Dérivés de pyrazole et leur utilisation comme inhibiteurs de raf
MA37712B1 (fr) Inhibiteurs macrocycliques de virus flaviviridae
TN2011000316A1 (fr) Derives de sulfonamides
MA32351B1 (fr) Derives d'aminodihydrothiazine a titre d'inhibiteurs de bace pour le traitement de la maladie d'alzheimer
TN2016000188A1 (fr) Derives de purines 2,6-substitues et leur utilisation dans le traitement de troubles proliferatifs.
MA31170B1 (fr) Dérivés de 2-amino-5,7-dihydro-6h-pyrrolo[3,4-d]pyrimidine servant d'inhibiteurs de la hsp-90 pour le traitement du cancer
MA38323A1 (fr) Dérivés pyrimidone et leur utilisation dans le traitement, l'amélioration ou la prévention d'une maladie virale
MA33745B1 (fr) Piperidines substituees qui accroissent l'activite de p53, et utilisation de ces composes
MA27801A1 (fr) Nouveaux composes heterocycliques pour le traitement des affections inflammatoires et allergiques, leur procede de preparation et compositions pharmaceutiques les contenant
MA29926B1 (fr) Derives de pyrazine
TNSN07022A1 (fr) Derives de pyridine
MA37405A1 (fr) Composés hétérocyclyle
MA40225B1 (fr) Composés dihydroisoquinolinone substitués
MX2008013583A (es) Compuestos del inhibidor de fosfoinositido 3-cinasa y composiciones farmaceuticas que los contienen.
TN2015000547A1 (fr) Composes heteroaromatiques et leur utilisation comme ligands de dopamine d1
MA31710B1 (fr) (carboxylalkylenephenyl)phényloxamides, procédés pour la production de ceux-ci et utilisation de ceux-ci en tant que medicament
MX2011012337A (es) Nuevos derivados de pirimidina y su uso en el tratamiento de cancer y de otras enfermedades.
NZ612909A (en) Processes for preparing isoquinolinones and solid forms of isoquinolinones